{"id":"azd8848","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"10-20%","effect":"Nasopharyngitis"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, AZD8848 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases. However, the exact mechanism of action may vary depending on the specific indication and disease being targeted.","oneSentence":"AZD8848 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:29.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT01560234","phase":"PHASE1","title":"AZD8848 Single Ascending Dose Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Healthy","enrollment":47},{"nctId":"NCT00999466","phase":"PHASE2","title":"The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Allergic Asthma","enrollment":60},{"nctId":"NCT01185080","phase":"PHASE2","title":"Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Allergic Rhinitis","enrollment":93},{"nctId":"NCT00688779","phase":"PHASE1","title":"Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Healthy, Allergic Rhinitis","enrollment":130},{"nctId":"NCT00770003","phase":"PHASE1","title":"Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Allergic Rhinitis","enrollment":103},{"nctId":"NCT01203124","phase":"PHASE1","title":"A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Healthy Volunteers","enrollment":55},{"nctId":"NCT01205867","phase":"PHASE1","title":"Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Butyrylcholinesterase Deficiency","enrollment":22},{"nctId":"NCT01818869","phase":"PHASE1","title":"To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Safety,, Tolerability,, Healthy Subjects","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD8848","genericName":"AZD8848","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD8848 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}